Cardizem

Angina Pectoris, Variant, Atrial Fibrillation, Proteinuria + 11 more

Treatment

6 FDA approvals

20 Active Studies for Cardizem

What is Cardizem

Diltiazem

The Generic name of this drug

Treatment Summary

Diltiazem is a medication used to treat high blood pressure and other cardiovascular conditions. It belongs to a class of drugs called non-dihydropyridine calcium channel blockers. It works by blocking the movement of calcium into the cells of the heart and blood vessels, which relaxes the muscles and lowers blood pressure. It is typically available in both oral and intravenous forms, and is sold under the brand names Cardizem and Tiazac. It is also used off-label for various conditions, such as anal fissures, migraine prevention, pulmonary hypertension, and rest-related cramps.

Cardizem

is the brand name

image of different drug pills on a surface

Cardizem Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Cardizem

Diltiazem

1982

656

Approved as Treatment by the FDA

Diltiazem, commonly known as Cardizem, is approved by the FDA for 6 uses which include Coronary Vasospasm and Coronary Artery Vasospasm .

Coronary Vasospasm

Helps manage Coronary Artery Vasospasm

Coronary Artery Vasospasm

Helps manage Coronary Artery Vasospasm

Anginal Pain

Helps manage Anginal Pain

Hypertensive disease

Helps manage High Blood Pressure (Hypertension)

Angina, Stable

Helps manage Chronic Stable Angina Pectoris

Angina Pectoris

Helps manage Anginal Pain

Effectiveness

How Cardizem Affects Patients

Diltiazem is a medication used to lower blood pressure and relax the blood vessels, which helps prevent strokes and heart attacks. It works by blocking certain calcium channels, which decreases the force and rate of the heartbeat. It also reduces the amount of pressure in the blood vessels, which helps to improve blood flow. Diltiazem is most effective in people with high blood pressure, and studies have shown that it can reduce diastolic blood pressure by up to 8.6 mmHg. Additionally, it has been shown to increase exercise tolerance and reduce the risk of stroke in hypertensive patients.

How Cardizem works in the body

Diltiazem works by blocking the slow calcium channels in the heart and blood vessels, which helps to reduce the amount of calcium entering the cells. This lowers the amount of calcium in the cells and helps the muscles in the heart and blood vessels to relax, lowering blood pressure. It also lowers the heart rate and oxygen demand, reducing the symptoms of chronic stable angina.

When to interrupt dosage

The suggested dosage of Cardizem is contingent upon the diagnosed state, for example prophylaxis of migraine headaches, Fissure;Anal and Anginal Pain. The portion of dosage also deviates as per the method of administration recorded in the table below.

Condition

Dosage

Administration

Angina Pectoris

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Atrial Fibrillation

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Coronary Vasospasm

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Angina Pectoris, Variant

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Proteinuria

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Hypertensive disease

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Angina, Stable

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Tachycardia, Supraventricular

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Cardiomyopathy, Dilated

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Migraine Disorders

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Diabetic Neuropathy

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Pulmonary Hypertension

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Fissure in Ano

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Muscle Cramp

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Warnings

Cardizem has a decalogue of contraindications, so it should not be amalgamated with the conditions in the table below.

Cardizem Contraindications

Condition

Risk Level

Notes

Heart Attack

Do Not Combine

accessory bypass tract

Do Not Combine

accessory bypass tract

Do Not Combine

Bradycardia

Do Not Combine

Ventricular Tachycardia

Do Not Combine

Bradycardia

Do Not Combine

Atrioventricular Block

Do Not Combine

Pulmonary Congestion

Do Not Combine

Shock, Cardiogenic

Do Not Combine

Hypotension

Do Not Combine

There are 20 known major drug interactions with Cardizem.

Common Cardizem Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Diltiazem.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Diltiazem.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Diltiazem.

Alfentanil

Major

The metabolism of Alfentanil can be decreased when combined with Diltiazem.

Amifostine

Major

Diltiazem may increase the hypotensive activities of Amifostine.

Cardizem Toxicity & Overdose Risk

The toxic dose of diltiazem in mice is between 415 and 740mg/kg, and in rats is between 560 and 810mg/kg. The toxic dose in dogs is over 50mg/kg, and 360mg/kg has been fatal to monkeys. Overdoses of diltiazem have been reported with doses ranging from less than 1g to 18g. Symptoms of overdose include slow heart rate, low blood pressure, heart block, and heart failure which can cause lightheadedness and fatigue. Treatment for overdose includes supportive care, vomiting, activated charcoal, atropine, isoproterenol,

image of a doctor in a lab doing drug, clinical research

Cardizem Novel Uses: Which Conditions Have a Clinical Trial Featuring Cardizem?

228 active clinical trials are underway to assess the efficacy of Cardizem in providing relief of Atrial Fibrillation, Coronary Artery Spasm and Paroxysmal Supraventricular Tachycardia (PSVT).

Condition

Clinical Trials

Trial Phases

Atrial Fibrillation

90 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3, Early Phase 1

Diabetic Neuropathy

6 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Pulmonary Hypertension

33 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1

Tachycardia, Supraventricular

2 Actively Recruiting

Phase 3, Phase 2

Angina, Stable

0 Actively Recruiting

Angina Pectoris, Variant

0 Actively Recruiting

Angina Pectoris

2 Actively Recruiting

Not Applicable, Phase 4

Cardiomyopathy, Dilated

1 Actively Recruiting

Not Applicable

Proteinuria

5 Actively Recruiting

Phase 2, Phase 3, Phase 4, Phase 1

Muscle Cramp

0 Actively Recruiting

Hypertensive disease

27 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Coronary Vasospasm

0 Actively Recruiting

Migraine Disorders

1 Actively Recruiting

Phase 3

Fissure in Ano

0 Actively Recruiting

Cardizem Reviews: What are patients saying about Cardizem?

5

Patient Review

5/7/2014

Cardizem for Supraventricular Cardiac Arrhythmia

This was used in ER to lower my heart rate. So far, it's been five months and I've only had one attack.

5

Patient Review

12/12/2018

Cardizem for High Blood Pressure

I've been on this generic medication for six months and just visited my cardiologist. I'm very pleased with the results- my blood pressure is now 136/76 and my pulse is 67. There have been no side effects that I'm aware of, so I would highly recommend this to others.

4.7

Patient Review

10/15/2015

Cardizem for Type of Angina Where Chest Pain Occurs at Rest

These pills have been instrumental in managing my chest pain at night. I was unable to sleep for weeks before taking this medication, but now I'm able to get a full night's rest.

3.7

Patient Review

11/1/2016

Cardizem for High Blood Pressure

I take 120 mg of this medication to help control my high blood pressure. I have found that if I take it at night, I wake up feeling faint and lightheaded. These symptoms subside by noon; however, this is still better than the other medications (Ace Inhibitors and Valsartan) that I've taken in the past.

3.7

Patient Review

12/28/2019

Cardizem for High Blood Pressure

I have experienced a number of concerning side effects since starting this medication, including but not limited to: excessive nosebleeds, an embarrassing cough, fatigue and insomnia, swollen legs, and dizzy spells. My doctor does not seem to be taking my complaints seriously.

3.7

Patient Review

10/3/2019

Cardizem for High Blood Pressure

I have found it difficult to adjust to this medication. I experience lightheadedness, muscle fatigue, heavy legs and falls, headaches, a runny nose, cough, muscle aches, and nausea. It has really impacted my lifestyle negatively.

3

Patient Review

12/15/2013

Cardizem for High Blood Pressure

I experienced dry mouth and headaches after taking this medication.

2.7

Patient Review

10/1/2013

Cardizem for High Blood Pressure

I had some really bad headaches even when I was taking the minimal dosage.

2.3

Patient Review

4/24/2013

Cardizem for High Blood Pressure

I had to go to the ER after taking this medicine because it caused my heart rate to drop too low. I also experienced weakness, dizziness, nausea, and shortness of breath. If you have any problems with this medicine, make sure to tell your doctor so they can prescribe something different.

2.3

Patient Review

8/25/2015

Cardizem for High Blood Pressure

I was really tired all the time, developed itchy sores, and began having very strange dreams. Additionally, I sweat a lot more than usual.

2

Patient Review

8/13/2014

Cardizem for High Blood Pressure

Cardizem has unfortunately given me some very unpleasant side effects, including leg swelling and heaviness, as well as joint and muscle pain. I'm going to speak with my doctor about changing medications soon.

2

Patient Review

4/28/2013

Cardizem for High Blood Pressure

My feet swelled to three times their normal size, I had bruises all over my body, and an abnormal rash on my penis that caused bleeding. As a heart transplant patient, you would think doctors would be more careful about potential interactions between drugs. It's a shame medical care has gotten this bad.

1.3

Patient Review

5/10/2015

Cardizem for High Blood Pressure

Unfortunately, this caused me to cough a lot.

1

Patient Review

10/1/2017

Cardizem for Supraventricular Cardiac Arrhythmia

The initial dizziness was so bad that it sent me back to the ER. The doctors told me "I'll adjust," but instead I experienced extreme fatigue and some balance disturbance. WORST: This medication is probably inappropriate for my condition. I was NOT experiencing angina, BP was not "elevated" but yo-yoing: 40 bpm to 120 bpm; back down, back up etc. Wait TWO MONTHS for Holder evaluation? On this stuff?
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about cardizem

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does Cardizem do for AFIB?

"The Calcium Channel antagonism decreases the ability of the SAN node to set the pace of the heart, and also decreases the conduction of electrical signals through the AV node. This makes it a useful medication for treating atrial arrhythmias such as atrial fibrillation, atrial flutter, and supraventricular tachycardias."

Answered by AI

Is Cardizem a good blood pressure medicine?

"Cardizem is a medication that prevents the movement of calcium into the cells of the heart and blood vessels, leading to the relaxation of the muscles. It is used to treat hypertension, or high blood pressure, either on its own or in combination with other medications."

Answered by AI

Is Cardizem a beta blocker?

"Cardizem and Lopressor are two separate types of drugs. Cardizem works by blocking calcium channels, while Lopressor is a beta-blocker."

Answered by AI

What is the drug Cardizem used for?

"Diltiazem is used to lower high blood pressure and prevent chest pain. By lowering blood pressure, it helps to prevent strokes, heart attacks, and kidney problems. When used regularly, diltiazem can decrease the number and severity of episodes of chest pain."

Answered by AI

Clinical Trials for Cardizem

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of Northwestern University in Chicago, United States.

Exercise Program for Atrial Fibrillation and Heart Failure

60 - 99
All Sexes
Chicago, IL

Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are very common conditions that often occur together and result in worsening symptoms and reduced quality of life (QoL). Limitations being able to participate in activities of daily living is a primary complaint for AF-HFpEF patients, yet effective strategies to address this issue remain limited. While exercise interventions targeting aerobic training (AT) are recommended for patients with AF and HFpEF, unique challenges exist in this patient population who tend to be older. Specifically, many older patients with AF and HFpEF have muscle weakness, sarcopenia and frailty, that can make aerobic-focused exercise difficult and less tolerable. This study proposes that starting with progressive resistance training (PRT) before aerobic exercise may overcome these issues by improving muscle strength, making AT more manageable, and leading to better health outcomes. The goal of this study is to assess whether a sequential exercise program, named 'PREACTIVE' improves how people feel, decrease the amount of symptoms, and their ability to participate in exercise and activities. This study will specifically test a sequenced exercise approach of resistance training followed by aerobic exercise to improve symptoms, and quality of life in AF-HFpEF.

Waitlist Available
Has No Placebo

Northwestern University

Deepika Laddu, PhD

Image of the FSU TMH Family Practice Residency Program in Tallahassee, United States.

Cannabidiol for Diabetic Neuropathy

40 - 70
All Sexes
Tallahassee, FL

The "Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot study (CBD-DPN1)" is a double-blinded, placebo-controlled, crossover pilot study evaluating the efficacy of Cannabidiol (CBD) and full-spectrum CBD (fsCBD) tinctures in treating Diabetic Peripheral Neuropathy (DPN)-associated pain. DPN is a common, highly distressing complication of diabetes, characterized by chronic pain and loss of sensory function, for which currently available treatments primarily offer only symptomatic relief. CBD and fsCBD are being investigated for their potential neuroprotective and analgesic effects by regulating inflammation and oxidative stress. The study aims to recruit 12 to 20 adult participants who have mild to moderate DPN. Subjects will receive either an active treatment (CBD isolate or fsCBD in MCT oil, dosed at 50 mg twice daily for a total of 100 mg daily) or a placebo during two sequential 6-week phases. The overall objective of this pilot phase is primarily methodological: to test and refine the clinical protocol, assess patient compliance and acceptability of the CBD formulations, and generate sufficient data to calculate the necessary sample size for a larger, definitive study. Efficacy will be measured using objective and subjective metrics, including DPN severity (DN4 Assessment Tool and DPNCheck™ for nerve conduction velocity) and pain level (PainDetect Questionnaire). Secondary outcomes include evaluating mood (HADS), sleep quality (MOS Sleep Scale), and quality of life (EQ-5D-5L).

Phase 1 & 2
Waitlist Available

the FSU TMH Family Practice Residency Program

Have you considered Cardizem clinical trials?

We made a collection of clinical trials featuring Cardizem, we think they might fit your search criteria.
Go to Trials
Image of Grand Island Pain Relief Center in Grand Island, United States.

BurstDR Spinal Cord Stimulation for Diabetic Neuropathy

18+
All Sexes
Grand Island, NE

This prospective, single-arm clinical study evaluates the therapeutic efficacy and feasibility of BurstDR spinal cord stimulation (SCS) using Abbott's Proclaim XR and Eterna systems in patients with painful diabetic neuropathy (PDN). Adults with confirmed PDN will undergo a one-week temporary SCS trial, and those achieving meaningful improvement (≥50% reduction in average pain on the Visual Analog Scale) will proceed to permanent implantation. Outcomes will be assessed at baseline, end of trial, and at 1-, 3-, and 6-month follow-up visits using validated instruments including VAS, DN4, DQoL, PSQ-3, the Patient Global Impression of Change, and the Clinician Global Impression of Change. All procedures follow standard clinical practice for SCS therapy. The study aims to characterize real-world effectiveness, patient-reported outcomes, feasibility of implementation, and device-related safety in a rural PDN population.

Waitlist Available
Has No Placebo

Grand Island Pain Relief Center

TriCity Research Center

Image of Inova Alexandria Hospital in Alexandria, United States.

Heparin Dosing for Blood Clots and Heart Conditions

18+
All Sexes
Alexandria, VA

The goal of this clinical trial study is to test whether a mathematical calculation, using the patient's gender, weight and kidney function, can better predict a patient's heparin goal dose than a flat number of units per patient weight can. Participants will have the first dose of heparin infusion calculated, after which if adjustments are needed, the Hospital's prebuilt table for results driven dosing for this purpose is used. The researchers will compare the time it takes for the participants to get to the desired goal using the patient's information for calculation versus patients in the past who received the medication using the flat rate. The hypothesis is that the patients with enhanced personal data, gender, weight and kidney function, included for the initial dose, will get to their goal lab value sooner and with less chance of delay or overshooting the goal. A quicker time to goal lab value is beneficial to patients in many ways, including earlier treatment of the clot or coronary issue that the patient is experiencing.

Phase 4
Waitlist Available

Inova Alexandria Hospital

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL

This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.

Waitlist Available
Has No Placebo

U Health (+1 Sites)

Ziad Zoghby, M.D., M.B.A.

Biobeat Technologies Ltd.

Have you considered Cardizem clinical trials?

We made a collection of clinical trials featuring Cardizem, we think they might fit your search criteria.
Go to Trials
Image of UPMC Presybeterian in Pittsburgh, United States.

Telaglenastat for Pulmonary Hypertension

18 - 75
All Sexes
Pittsburgh, PA

The research study is being conducted to evaluate the effectiveness of a drug called Telaglenastat in adults diagnosed with Pulmonary Hypertension (PH). PH is a progressive condition that affects the arteries in the lungs, specifically the pulmonary arteries, which carry blood from the right side of the heart to the lungs. Telaglenastat is not currently approved by the Food and Drug Administration for the treatment of PH. However, the study investigators believe that Telaglenastat may help lower blood pressure in the lungs and improve both heart and lung function. It is important to note that the drug will not be available to participants once the study concludes.

Phase 1 & 2
Waitlist Available

UPMC Presybeterian

Michael Risbano, MD

Have you considered Cardizem clinical trials?

We made a collection of clinical trials featuring Cardizem, we think they might fit your search criteria.
Go to Trials